Further, Salmonella Shigella Agar (SS) and Xylose-Lysine Deoxycholate Agar (XLD agar) (HiMedia, USA) were streaked with sterile loops carrying inoculums took from Selenite cystine and Tetrathionate ...

Lab-grown human intestinal organoids enabled precise mapping of the genes Shigella bacteria require to invade and colonize human gut tissue. Of approximately 5,000 genes, about 100 are essential ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial design and fundraising, framed the deal as a way to get the vaccine to ...

Hyderabad-based vaccine maker Bharat Biotech International and global biopharma major GSK have announced a collaboration to advance development of latter’s Shigella vaccine candidate altSonflex1 ...

Vaccine maker Bharat Biotech International entered into a partnership with GSK plc to develop and potentially use the Shigella vaccine candidate to prevent Shigellosis. Shigellosis. is a severe ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine for potential distribution in low- and middle-income countries. GSK ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International. The U.K. pharma company on Thursday said the agreement paves the way for the development ...

India is also impacted. A 2021 study published in the Indian Journal of Medical Biology— Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century — talks about how ...

Thanks to lab-grown miniature intestines, researchers at Uppsala University have successfully mapped how aggressive Shigella bacteria infect the human gut. The study opens the door to using ...

Hyderabad: Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing, today announced that it has partnered with GSK plc (LSE/NYSE: GSK) for the ongoing ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early ...